AION — Aion Therapeutic Income Statement
0.000.00%
Last trade - 00:00- CA$8.23m
- CA$9.92m
Annual income statement for Aion Therapeutic, fiscal year end - April 30th, CAD millions except per share, conversion factor applied.
2019 April 30th | 2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.93 | 0.659 | 8.27 | 3.82 | 0.148 |
| Operating Profit | -4.93 | -0.659 | -8.27 | -3.82 | -0.148 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.93 | -0.673 | -8.27 | -3.82 | -0.257 |
| Net Income After Taxes | -4.93 | -0.673 | -8.27 | -3.82 | -0.257 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.93 | -0.673 | -8.27 | -3.82 | -0.257 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.93 | -0.673 | -8.27 | -3.82 | -0.257 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.088 | -0.037 | -0.034 | -0.02 | -0.007 |